Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease.

Cardiovascular Revascularization Medicine(2017)

Cited 20|Views0
No score
Abstract
Administration of trimetazidine in a dose of 35mg twice daily orally in conjunction with standard early saline hydration is an effective method to prevent or reduce the incidence of contrast-induced renal dysfunction following the administration of contrast media during coronary angiography procedures in patients with mild-moderate basal renal insufficiency.
More
Translated text
Key words
Contrast induced nephropathy,Coronary angiography
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined